Cargando…

International Chronic Ocular Graft-vs-Host-Disease (GVHD) Consensus Group: Proposed Diagnostic Criteria for Chronic GVHD (Part I)

The International Chronic Ocular GVHD Consensus Group held 4 working meetings to define new diagnostic metrics for chronic ocular graft-versus-host disease (GVHD). After considering the factors currently used to diagnose chronic ocular GVHD, the Consensus Group identified 4 subjective and objective...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ogawa, Yoko, Kim, Stella K., Dana, Reza, Clayton, Janine, Jain, Sandeep, Rosenblatt, Mark I., Perez, Victor L., Shikari, Hasanain, Riemens, Anjo, Tsubota, Kazuo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2013
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3851919/ https://www.ncbi.nlm.nih.gov/pubmed/24305504 http://dx.doi.org/10.1038/srep03419

Ejemplares similares

Cascade of Inflammatory, Fibrotic Processes, and Stress-Induced Senescence in Chronic GVHD-Related Dry Eye Disease
por: Ogawa, Yoko, et al.
Publicado: (2021)

Diagnosis and treatment of pulmonary chronic GVHD: report from the consensus conference on clinical practice in chronic GVHD
por: Hildebrandt, G C, et al.
Publicado: (2011)

Chronic GvHD NIH Consensus Project Biology Task Force: evolving path to personalized treatment of chronic GvHD
por: Buxbaum, Nataliya P., et al.
Publicado: (2022)

Nonrelapse mortality among patients diagnosed with chronic GVHD: an updated analysis from the Chronic GVHD Consortium
por: DeFilipp, Zachariah, et al.
Publicado: (2021)

Chronic gvhd dictionary—eurograft cost action initiative consensus report
por: Zelić Kerep, Ana, et al.
Publicado: (2022)

Posttransplant cyclophosphamide vs tacrolimus–based GVHD prophylaxis: lower incidence of relapse and chronic GVHD
por: Maurer, Katie, et al.
Publicado: (2023)

Chronic GVHD after steroid-sensitive, -dependent, and -refractory acute GVHD: incidence and clinical outcomes
por: Herzog, Shannon, et al.
Publicado: (2023)

Investigator feedback about the 2005 NIH diagnostic and scoring criteria for chronic GVHD
por: Inamoto, Yoshihiro, et al.
Publicado: (2014)

Targeting Cytokines in GVHD Therapy
por: Kumar, Sandeep, et al.
Publicado: (2017)

High incidence of thromboembolism in patients with chronic GVHD: association with severity of GVHD and donor-recipient ABO blood group
por: El Jurdi, Najla, et al.
Publicado: (2021)

Letermovir reduces chronic GVHD risk in calcineurin inhibitor-free GVHD prophylaxis after hematopoietic cell transplantation
por: Lorentino, Francesca, et al.
Publicado: (2022)

GVHD Prophylaxis 2020
por: Gooptu, Mahasweta, et al.
Publicado: (2021)

Mesenchymal stem cell as salvage treatment for refractory chronic GVHD
por: Weng, J Y, et al.
Publicado: (2010)

Developing role of B cells in the pathogenesis and treatment of chronic GVHD
por: Li, Xiaoping, et al.
Publicado: (2018)

Chronic GVHD: predictive factor for rhinosinusitis in bone marrow transplantation
por: Ortiz, Erica, et al.
Publicado: (2015)

Novel and Promising Strategies for Therapy of Post-Transplant Chronic GVHD
por: Kostareva, Irina, et al.
Publicado: (2022)

Inflammasome effects in GvHD
por: Koehn, Brent H., et al.
Publicado: (2015)

Editorial: Interferons and GvHD
por: Kim, Boram, et al.
Publicado: (2022)

Regulatory T Cells in GVHD Therapy
por: Guo, Wen-wen, et al.
Publicado: (2021)

Milestones in acute GVHD pathophysiology
por: Socie, Gerard, et al.
Publicado: (2022)

Utility of eGVHD App for bedside GVHD assessment in a high-volume BMT center
por: Chhabra, Prashant, et al.
Publicado: (2023)

Development and validation of a diagnostic model for the identification of chronic ocular graft-versus-host disease (oGVHD)
por: Shen, Zhan, et al.
Publicado: (2023)

More evidence for low-dose IL-2 for chronic GVHD in children
por: Levine, John E.
Publicado: (2023)

Gut-grabbing T cells trigger GVHD
por: Van Epps, Heather L.
Publicado: (2005)

Impact of oral microbiota on pathophysiology of GVHD
por: Yamamoto, Akira, et al.
Publicado: (2023)

The utility of biomarkers in acute GVHD prognostication
por: Spyrou, Nikolaos, et al.
Publicado: (2023)

Therapeutic Potential of a Senolytic Approach in a Murine Model of Chronic GVHD
por: Raman, Deepika, et al.
Publicado: (2023)

PB2445: THE ROLE OF MEDITERRANEAN DIET IN CHRONIC GVHD: A PILOT STUDY
por: Brambilla, Giulia, et al.
Publicado: (2023)

Human Effectors of Acute and Chronic GVHD Overexpress CD83 and Predict Mortality
por: Holtan, Shernan G., et al.
Publicado: (2023)

Humoral and Cellular Immune Response to Sars-Cov-2 Vaccination in Patients with Chronic GVHD
por: Manjappa, Shivaprasad, et al.
Publicado: (2022)

Extracorporeal photopheresis as an immunomodulatory treatment modality for chronic GvHD and the importance of emerging biomarkers
por: Bojanic, Ines, et al.
Publicado: (2023)

Steroid-Refractory Acute GVHD: Predictors and Outcomes
por: Westin, Jason R., et al.
Publicado: (2011)

Antibody- and aptamer-strategies for GvHD prevention
por: Oelkrug, Christopher, et al.
Publicado: (2015)

Established and Emerging Treatments of Skin GvHD
por: Link-Rachner, Cornelia S., et al.
Publicado: (2022)

Rearrangement of T Cell genome architecture regulates GVHD
por: Sun, Yaping, et al.
Publicado: (2022)

ER stress: an emerging regulator in GVHD development
por: Choi, Hee-Jin, et al.
Publicado: (2023)

Natalizumab for GVHD: too little or too late?
por: Quann, Kevin, et al.
Publicado: (2023)

Effects of aGVHD and cGVHD on Survival Rate in Patients with Acute Myeloid Leukemia after Allogeneic Stem Cell Transplantation
por: Shokouhi, Shabnam, et al.
Publicado: (2015)

Reduced intensity conditioning increases risk of severe cGVHD: identification of risk factors for cGVHD in a multicenter setting
por: Afram, Gabriel, et al.
Publicado: (2018)

A nomogram model for predicting ocular GVHD following allo-HSCT based on risk factors
por: Wang, Wen-hui, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_f57p03vbu52ou4244a8vrj8bse